91350-53-7

Basic information

• Product Name: 2-amino-4-(4-methoxybenzyl)thiazole
• Synonyms: 2-amino-4-(4-methoxybenzyl)thiazole
• CAS NO: 91350-53-7
• Molecular Weight: 220.295
• Mol File: 91350-53-7.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 2-amino-4-(4-methoxybenzyl)thiazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-amino-4-(4-methoxybenzyl)thiazole(91350-53-7)
• EPA Substance Registry System: 2-amino-4-(4-methoxybenzyl)thiazole(91350-53-7)

Safety Data

• Hazardous Substances Data: 91350-53-7(Hazardous Substances Data)

Usage

General Description

2-amino-4-(4-methoxybenzyl)thiazole is a chemical compound that is a thiazole derivative with a benzyl moiety substituted at the 4-position and an amino group at the 2-position. It is commonly used in pharmaceutical research and drug development due to its potential therapeutic properties. 2-amino-4-(4-methoxybenzyl)thiazole has been studied for its potential antifungal and antibacterial activities. Its structure and reactivity make it a valuable building block for the synthesis of various biologically active molecules. Additionally, it has been investigated for its potential as an anti-cancer agent and as a therapeutic target for neurological disorders. Overall, 2-amino-4-(4-methoxybenzyl)thiazole is a versatile and important compound in medicinal chemistry with a wide range of potential applications.

Upstream product

• 24253-13-2 4-methoxybenzylchloromethyl ketone 
• 17356-08-0 thiourea 
• 696-62-8 para-iodoanisole 
• 37614-59-8 4-(4-methoxyphenyl)prop-2-yn-1-ol 
• 173019-85-7 3-bromo-1-(4-methoxyphenyl)propyne 
• 924906-80-9 Methanesulfonic acid 3-(4-methoxy-phenyl)-prop-2-ynyl ester 
• 4693-91-8 4-methoxyphenyl-acetic chloride 
• 20772-13-8 1-bromo-3-(4-methoxyphenyl)-2-propanone 
• 104-01-8 4-Methoxyphenylacetic acid 
• 76-05-1 trifluoroacetic acid 

Relevant articles and documents

MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF

Formulations and methods for reducing blood glucose and/or increasing insulin signaling in a subject have been developed. The formulations include SBI-477 and compounds based on SBI-477 i.e., SBI-477 analogs (collectively, SBI-477 compounds) and/or Mondo family inhibitors, in an effective amount to inhibit intracellular lipid accumulation and/or increase cellular glucose uptake when compared to levels in a control subject not administered the composition. Also disclosed are methods of reducing intracellular lipid accumulation and/or increase glucose uptake in a subject in need thereof. The method includes administering to the subject an effective amount of SBI-477 compounds and/or Mondo family inhibitor to reducing intracellular lipid accumulation and/or increase glucose uptake in the subject. Also disclosed are method for treating one or more Myc-driven cancers, including neuroblastoma, lung squamous cell carcinoma/lung adenocarcinoma, liver hepatocellular carcinoma, colon adenocarcinoma, acute myeloid leukemia, and breast invasive carcinoma.

Domino alkylation-cyclization reaction of propargyl bromides with thioureas/thiopyrimidinones: A new facile synthesis of 2-aminothiazoles and 5H-thiazolo[3,2-α]pyrimidin-5-ones

A new synthesis of 2-aminothiazoles and 5H-thiazolo[ 3,2-α]pyrimidin- 5-ones was developed as a domino alkylation-cyclization reaction of propargyl bromides with thioureas and thiopyrimidinones, respectively. Domino reactions were performed under microwave irradiation leading to desired compounds in a few minutes and high yields. Georg Thieme Verlag Stuttgart.

Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof

The present invention relates to new class of non-steroidal compounds which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory- and immune-associ